Biomarker & Intervention Discovery

Peripheral Artery Disease

Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.

Disease Overview

Spontaneous remission
Not established
Best-intervention remission
Gap size
Primary barrier
Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.

EDN1 18F2 238IL6 173LDLR 48NOS3 0PCSK9 170SERPINC1 46
Therapeutic Agent Effect Direction Evidence Tier Potency Source
OXYGEN THERAPY ? unclear Mechanistic
CELECOXIB ? unclear Mechanistic
TAMOXIFEN ? unclear Mechanistic
DOXORUBICIN HYDROCHLORIDE ? unclear Mechanistic
THIOURACIL ? unclear Mechanistic
ALPROSTADIL ? unclear Mechanistic
ANTIPLATELET AGENT ? unclear Mechanistic
ANTICONVULSANT AGENT ? unclear Mechanistic
BUDESONIDE ? unclear Mechanistic
LANREOTIDE ACETATE ? unclear Mechanistic
CANDESARTAN CILEXETIL ? unclear Mechanistic
ANESTHETIC AGENT ? unclear Mechanistic
BEVACIZUMAB ? unclear Mechanistic
PROTEIN SYNTHESIS INHIBITOR ? unclear Mechanistic
DEFEROXAMINE ? unclear Mechanistic
NORETHINDRONE ACETATE ? unclear Mechanistic
INSULIN, REGULAR, HUMAN ? unclear Mechanistic
MURAGLITAZAR ? unclear Mechanistic
Therapeutic Agent Effect Direction Evidence Tier Potency Source
DESIRUDIN inhibits Mechanistic
BIVALIRUDIN inhibits Mechanistic
TAMOXIFEN ? unclear Mechanistic
PEGMUSIRUDIN ? unclear Mechanistic
FLOVAGATRAN ? unclear Mechanistic
ANISINDIONE ? unclear Mechanistic
HEPARIN ? unclear Mechanistic
CATECHIN ? unclear Mechanistic
DABIGATRAN inhibits Mechanistic
DABIGATRAN ETEXILATE MESYLATE inhibits Mechanistic
QUERCETIN ? unclear Mechanistic
ODIPARCIL ? unclear Mechanistic
DPOC-4088 ? unclear Mechanistic
LUSUTROMBOPAG ? unclear Mechanistic
ICHORCUMAB inhibits Mechanistic
PYRIDOXAL PHOSPHATE ANHYDROUS ? unclear Mechanistic
BORTEZOMIB ? unclear Mechanistic 13000.0 nM (Ki)
ANTITHROMBIN ALFA inhibits Mechanistic
SR-123781A ? unclear Mechanistic
ENOXAPARIN SODIUM ? unclear Mechanistic
CYANIDIN ? unclear Mechanistic
CHEMBL:CHEMBL586628 ? unclear Mechanistic
AZD-8165 ? unclear Mechanistic
STAUROSPORINE inhibits Mechanistic
AVATROMBOPAG ? unclear Mechanistic
HIRUDIN ? unclear Mechanistic
CYANIN ? unclear Mechanistic
COMPOUND 2C [PMID: 24900538] inhibits Mechanistic
SILIBININ ? unclear Mechanistic
EP-217609 ? unclear Mechanistic
APRAMIDE A ? unclear Mechanistic
EPICATECHIN ? unclear Mechanistic
ARGATROBAN inhibits Mechanistic
MELAGATRAN ? unclear Mechanistic 4700.0 nM (IC50)
ATECEGATRAN METOXIL inhibits Mechanistic
ASPIRIN TRELAMINE ? unclear Mechanistic
VITAMIN K3 ? unclear Mechanistic
XIMELAGATRAN inhibits Mechanistic
CHEMBL:CHEMBL1083499 ? unclear Mechanistic
DABIGATRAN ETEXILATE ? unclear Mechanistic

Showing top 40 of 238 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CISPLATIN ? unclear Mechanistic
ZILTIVEKIMAB ~ modulates Mechanistic
CHINESE HERBS ? unclear Mechanistic
PF-04236921 inhibits Mechanistic
MRA 003 US inhibits Mechanistic
SIGNAL TRANSDUCTION INHIBITOR ? unclear Mechanistic
BINETRAKIN ? unclear Mechanistic
IBUDILAST ? unclear Mechanistic
INSULIN, REGULAR, HUMAN ? unclear Mechanistic
SILTUXIMAB inhibits Mechanistic
METRONIDAZOLE ? unclear Mechanistic
CLAZAKIZUMAB inhibits Mechanistic
GALLIUM NITRATE ? unclear Mechanistic
INTERFERON ALFA-2B ? unclear Mechanistic
DULOXETINE HYDROCHLORIDE ? unclear Mechanistic
MEDI-5117 inhibits Mechanistic
GEMFIBROZIL ? unclear Mechanistic
BIAFINE CREAM ? unclear Mechanistic
ETANERCEPT ? unclear Mechanistic
ELSILIMOMAB inhibits Mechanistic
SAQUINAVIR ? unclear Mechanistic
INFLIXIMAB ? unclear Mechanistic
LINEZOLID ? unclear Mechanistic
IFOSFAMIDE ? unclear Mechanistic
OLOKIZUMAB inhibits Mechanistic
HMG-COA REDUCTASE INHIBITOR ? unclear Mechanistic
MIDOSTAURIN ? unclear Mechanistic
SELENIUM ? unclear Mechanistic
SIRUKUMAB inhibits Mechanistic
PEGINTERFERON ALFA-2B ? unclear Mechanistic
ECHINACEA PREPARATION ? unclear Mechanistic
ENZYME INHIBITOR ? unclear Mechanistic
FENOFIBRATE MICRONIZED ? unclear Mechanistic
VITAMIN K ? unclear Mechanistic
PEGINTERFERON ALFA-2A ? unclear Mechanistic
RIBAVIRIN ? unclear Mechanistic
VITAMIN A PALMITATE ? unclear Mechanistic
ARSENIC TRIOXIDE ? unclear Mechanistic
DIHYDROSPHINGOSINE ? unclear Mechanistic
LEVOFLOXACIN ANHYDROUS ? unclear Mechanistic

Showing top 40 of 173 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
HMG-COA REDUCTASE INHIBITOR ? unclear Mechanistic
GLUCAGON (RDNA) ? unclear Mechanistic
ATENOLOL ? unclear Mechanistic
VITAMIN A ? unclear Mechanistic
COLESTIPOL HYDROCHLORIDE ? unclear Mechanistic
HEPARIN CALCIUM ? unclear Mechanistic
CHEMBL:CHEMBL233611 ? unclear Mechanistic
TRIBUTYRIN ? unclear Mechanistic
RECOMBINANT TRANSFORMING GROWTH FACTOR ? unclear Mechanistic
CHOLESTYRAMINE RESIN ? unclear Mechanistic
GEMFIBROZIL ? unclear Mechanistic
EPOETIN ALFA ? unclear Mechanistic
TETRACYCLINE ? unclear Mechanistic
HALOPERIDOL DECANOATE ? unclear Mechanistic
MIPOMERSEN ? unclear Mechanistic
PHYTOESTROGEN ? unclear Mechanistic
ANTIVIRAL AGENT ? unclear Mechanistic
FAT EMULSION ? unclear Mechanistic
VERAPAMIL ? unclear Mechanistic
LOMITAPIDE MESYLATE ? unclear Mechanistic
SOY PROTEIN ISOLATE ? unclear Mechanistic
ANTIBIOTIC ? unclear Mechanistic
BUTYRIC ACID ? unclear Mechanistic
ACTH ? unclear Mechanistic
ALIROCUMAB ? unclear Mechanistic
INCLISIRAN ? unclear Mechanistic
LOVASTATIN ? unclear Mechanistic
ACETYLCYSTEINE ? unclear Mechanistic
ROSUVASTATIN ? unclear Mechanistic
PRAVASTATIN SODIUM ? unclear Mechanistic
EVINACUMAB ? unclear Mechanistic
CHEMBL114890 activates Mechanistic 700.0 nM (EC50)
CHEMBL114705 activates Mechanistic 1200.0 nM (EC50)
CHEMBL115304 activates Mechanistic 1300.0 nM (EC50)
CHEMBL324616 activates Mechanistic 700.0 nM (EC50)
CHEMBL115205 activates Mechanistic 4000.0 nM (EC50)
CHEMBL112449 activates Mechanistic 1000.0 nM (EC50)
CHEMBL419400 activates Mechanistic 7000.0 nM (EC50)
CHEMBL419763 activates Mechanistic 1700.0 nM (EC50)
CHEMBL419042 activates Mechanistic 2000.0 nM (EC50)

Showing top 40 of 48 agents ranked by evidence tier.

Pipeline results not yet available for this target. Run the pipeline to populate.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
ALIROCUMAB inhibits Mechanistic
ONGERICIMAB inhibits Mechanistic
TAFOLECIMAB inhibits Mechanistic
LOMITAPIDE MESYLATE ? unclear Mechanistic
EVOLOCUMAB inhibits Mechanistic
RG-7652 inhibits Mechanistic
BOCOCIZUMAB inhibits Mechanistic
FROVOCIMAB ? unclear Mechanistic
RALPANCIZUMAB inhibits Mechanistic
LERODALCIBEP inhibits Mechanistic
INCLISIRAN ? unclear Mechanistic
INCLISIRAN SODIUM ? unclear Mechanistic
DIPHENYL BORINIC ACID inhibits Mechanistic 30000.0 nM (Ki)
PHENYL BUTYL BORINIC ACID inhibits Mechanistic 1000.0 nM (Ki)
CHEMBL4107804 inhibits Mechanistic 3200.0 nM (IC50)
CHEMBL4107907 inhibits Mechanistic 1700.0 nM (IC50)
CHEMBL4114159 inhibits Mechanistic 800.0 nM (IC50)
CHEMBL4108338 inhibits Mechanistic 1500.0 nM (IC50)
CHEMBL4107714 inhibits Mechanistic 1500.0 nM (IC50)
CHEMBL4110311 inhibits Mechanistic 9500.0 nM (IC50)
CHEMBL4107559 inhibits Mechanistic 1800.0 nM (IC50)
CHEMBL4114106 inhibits Mechanistic 1500.0 nM (IC50)
CHEMBL4109097 inhibits Mechanistic 11700.0 nM (IC50)
CHEMBL4108330 inhibits Mechanistic 2300.0 nM (IC50)
CHEMBL4109114 inhibits Mechanistic 4500.0 nM (IC50)
CHEMBL3961039 inhibits Mechanistic 7300.0 nM (IC50)
CHEMBL4112247 inhibits Mechanistic 10700.0 nM (IC50)
CHEMBL4109308 inhibits Mechanistic 800.0 nM (IC50)
CHEMBL4109014 inhibits Mechanistic 11820.0 nM (IC50)
CHEMBL4108567 inhibits Mechanistic 3800.0 nM (IC50)
CHEMBL4111131 inhibits Mechanistic 18000.0 nM (IC50)
CHEMBL4115372 inhibits Mechanistic 1700.0 nM (IC50)
CHEMBL4106481 inhibits Mechanistic 3050.0 nM (IC50)
CHEMBL4108186 inhibits Mechanistic 5610.0 nM (IC50)
CHEMBL4115360 inhibits Mechanistic 5800.0 nM (IC50)
CHEMBL4114503 inhibits Mechanistic 25300.0 nM (IC50)
CHEMBL4108540 inhibits Mechanistic 2970.0 nM (IC50)
CHEMBL4109409 inhibits Mechanistic 5750.0 nM (IC50)
CHEMBL4109932 inhibits Mechanistic 14300.0 nM (IC50)
CHEMBL4106569 inhibits Mechanistic 16800.0 nM (IC50)

Showing top 40 of 170 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
TINZAPARIN SODIUM activates Mechanistic
ELTROMBOPAG ? unclear Mechanistic
PROGESTERONE ? unclear Mechanistic
FONDAPARINUX activates Mechanistic
AVATROMBOPAG ? unclear Mechanistic
ESTRADIOL VALERATE ? unclear Mechanistic
NADROPARIN CALCIUM activates Mechanistic
SULODEXIDE ? unclear Mechanistic
MECAMYLAMINE inhibits Mechanistic
[3H]Α-BUNGAROTOXIN inhibits Mechanistic
BEMIPARIN SODIUM activates Mechanistic
ATRACURIUM inhibits Mechanistic
LUSUTROMBOPAG ? unclear Mechanistic
SEMULOPARIN SODIUM inhibits Mechanistic
SYNTHETIC CONJUGATED ESTROGENS, A ? unclear Mechanistic
CARBOPLATIN ? unclear Mechanistic
HEPARIN activates Mechanistic
ANTITHROMBIN ALFA ? unclear Mechanistic
GEMCITABINE ? unclear Mechanistic
DANAPAROID SODIUM activates Mechanistic
GALLAMINE TRIETHIODIDE inhibits Mechanistic
PARNAPARIN SODIUM activates Mechanistic
2-O, 3-O DESULFATED HEPARIN ? unclear Mechanistic
WAGLERIN-1 inhibits Mechanistic
Α-CONOTOXIN GI inhibits Mechanistic
DELPARANTAG ? unclear Mechanistic
UNFRACTIONATED HEPARIN ? unclear Mechanistic
[125I]Α-BUNGAROTOXIN inhibits Mechanistic
Α-CONOTOXIN MI inhibits Mechanistic
ENOXAPARIN SODIUM activates Mechanistic
DOCIPARSTAT SODIUM ? unclear Mechanistic
HEPARIN CALCIUM activates Mechanistic
Α-BUNGAROTOXIN inhibits Mechanistic
PANCURONIUM inhibits Mechanistic
ARDEPARIN SODIUM activates Mechanistic
SUCCINYLCHOLINE activates Mechanistic
HEPARIN SODIUM ? unclear Mechanistic
DALTEPARIN SODIUM ? unclear Mechanistic
FONDAPARINUX SODIUM ? unclear Mechanistic
CHEMBL609990 inhibits Mechanistic 58.0 nM (Kd)

Showing top 40 of 46 agents ranked by evidence tier.


Clinical Trials

Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-03.

NCT07144150 Phase: NA Started: 2026-04-17

The primary objective of the study is to evaluate the long-term safety and effectiveness of the Advance Evero™ 18 Everolimus-coated Percutaneous Transluminal Angioplasty Balloon Catheter (hereafter referred to as the Evero drug-coated balloon \[DCB\]) in the treatment of the femoropopliteal artery l...

NCT05699005 Phase: PHASE1 Started: 2023-09-18

This multicenter randomized controlled trial compare two transfusion strategies of red blood cells transfusion in patients supported by veno-arterial extracorporeal membrane oxygenation for refractory cardiogenic shock. An individualized transfusion strategy based on ScVO2 level, is compared to a c...

NCT06909565 Phase: PHASE4 Started: 2025-07-23

V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin th...

NCT06544135 Phase: N/A Started: 2025-04-14

This is a preliminary prospective observational study measuring change in lower extremity temperature in response to revascularization procedure. The main question this study aims to answer is: \- Are temperature measurements from a forward looking infrared (FLIR) camera of the lower extremity use...

NCT07465627 Phase: N/A Started: 2026-07

Chronic limb threatening ischemia (CLTI) represents the most advanced stage of peripheral arterial disease (PAD) and is characterized by ischemic rest pain, non-healing wounds, or ischemic gangrene. High-risk PAD populations including patients with end-stage renal disease and or diabetes also experi...

NCT04800276 Phase: NA Started: 2021-02-11

The prevalence of peripheral arterial disease is 12.2% in France. Intermittent claudication is the most common symtom of this disease. During physical exercise, such as walking, blood oxygen (O2) requirements increase. The development of atherosclerosis in the lower limbs, causes narrowing of the ar...

NCT03982693 Phase: PHASE3 Started: 2019-03-19

TACT3a is a double blind, placebo-controlled, randomized trial to test a novel therapy, edetate disodium-based chelation of environmentally acquired toxic metals, to reduce cardiovascular events including amputation in high-risk diabetic patients.

NCT03529019 Phase: EARLY_PHASE1 Started: 2018-10-02

A prospective pilot study examining nutritional supplements among vascular surgery patients with Critical Limb Ischemia (CLI). CLI patients have a high rate of malnutrition and has the potential to benefit greatly from nutritional intervention. The investigators plan to evaluate nutrition and functi...

NCT07672249 Phase: N/A Started: 2026-06-16

Peripheral arterial disease involving the iliac arteries is a common manifestation of systemic atherosclerosis and a major cause of lifestyle-limiting claudication and chronic limb-threatening ischemia. Endovascular iliac artery stenting has become the preferred treatment strategy for most iliac les...

NCT04110327 Phase: N/A Started: 2019-10-31

Non-randomized, multicenter, combined prospective and retrospective cohort analysis consisting of a single arm treated with the MicroStent™ System.

NCT07619885 Phase: PHASE1 Started: 2026-06

CG-0255 is a novel investigational prodrug of the active metabolite of Plavix®, but with different active metabolite conversion routes. This is a randomized, open-label and Plavix®-controlled study to compare the PK and PD of CG-0255 Besylate and Plavix® in healthy participants.

NCT06477289 Phase: N/A Started: 2024-09-16

This study will examine sleep disordered breathing and sleep quality in participants (ages 12-25) diagnosed with sickle cell disease of any genotype. We will utilize remote peripheral arterial tonometry (PAT) and questionnaires to evaluate difficulties with sleep. PAT assessments will occur remotely...

NCT07350499 Phase: N/A Started: 2026-02-13

The study is designed to evaluate the short-term and long-term clinical performance and safety of the Symphony and Prodigy thrombectomy systems used in endovascular procedures across the peripheral or pulmonary vasculature.

NCT07655206 Phase: NA Started: 2026-06-23

Peripheral arterial disease (PAD) is a chronic atherosclerotic condition associated with impaired mobility, reduced quality of life, cardiovascular events, and risk of lower limb amputation. Although supervised exercise therapy (SET) is recommended for symptomatic PAD, access and adherence remain li...

NCT02795052 Phase: NA Started: 2016-06

This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain ne...


Agents Found By Disease-Level Search

Searched directly from “Peripheral Artery Disease” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 7-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."

Part of the Open Source Medicine Foundation Network

Open Source Medicine Foundation The OSMF hub — advancing open-source biomedical research infrastructure, tools, and evidence synthesis.
SpikeProtein.site Database and research resource on SARS-CoV-2 spike protein biology, persistence, and clinical implications.
Vaccine Data Navigator Open-access navigation tool for vaccine adverse event reporting and surveillance data.
VitalScan4PACVS Remote physiological monitoring study for post-acute COVID-19 vaccination syndrome.
PACVS Research Summit Annual summit convening researchers, clinicians, and patients on PACVS science.